OIL optiscan imaging limited

Good signs ...., page-1168

  1. 7,523 Posts.
    lightbulb Created with Sketch. 1189
    Optiscan teams up with US drugmaker to support FDA submissions


    Optiscan Imaging has fired a major shot in a bid to expand into the lucrative United States medical imaging market by inking a blockbuster five-year deal with American pharmaceutical outfit Long Grove Pharmaceuticals.


    Optiscan already uses the dye with its InVue fluorescence-based endomicroscopic imaging technology.


    The two companies have teamed up to explore and support new clinical uses for the injectable dye and will initially focus on breast surgery. The deal is expected to expand into gastrointestinal endoscopy, robotic-assisted surgery and laparoscopic procedures.



    Optiscan management said the deal showed an increasing number of healthcare companies were interested in working with Optiscan. This type of collaborative agreement could prompt more surgeons to use real-time imaging during surgery, potentially redefining disease treatment to improve patient outcomes.



    With the global digital health and surgical tech market booming, Optiscan’s alliance with Long Grove appears to mark a pivotal moment in its US expansion journey. It could well pave the way for a wave of new FDA approvals, commercial partnerships and life-saving clinical applications.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
10.5¢
Change
0.000(0.00%)
Mkt cap ! $87.71M
Open High Low Value Volume
10.5¢ 10.5¢ 10.5¢ $12.09K 115.2K

Buyers (Bids)

No. Vol. Price($)
1 480 10.5¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 4 1
View Market Depth
Last trade - 10.04am 31/07/2025 (20 minute delay) ?
OIL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.